About this episode
Economist Alex Tabarrok joins Bob to review Trump’s executive order on prescription drug pricing. They explore how price discrimination works in global pharmaceutical markets, the unintended consequences of importation policies, and why U.S. consumers often pay more—yet benefit most from drug innovation. Tabarrok also critiques the FDA’s role in delaying treatments and explains how regulatory reform, not price caps, could make healthcare more affordable and effective.
- Alex's Article, "Econ 101 is Underrated: Pharma Price Controls": Mises.org/HAP500a
The Mises Institute is giving away 100,000 copies of Murray Rothbard’s, What Has Government Done to Our Money? Get your free copy at Mises.org/HAPodFree
Get every episode summarized
Each time The Human Action Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Human Action Podcast
Robert Aro on the Fed's Reverse Repo Trick
The Human Action Podcast
Luke Gromen on the Strait of Hormuz and Supply Chain Collapse
The Human Action Podcast
Bob Responds to Randall Wray on Sectoral Balances
The Human Action Podcast
Cantillon Effects and the Politics of Money Creation
The Human Action Podcast